Sertindole, in contrast to clozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment

European Journal of Pharmacology

Volumn 542, Issue 1-3, 2006, Pages 108-115

  Didriksen, Michael ^a   Kreilgaard, Mads ^a   Arnt, Jørn ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

(Rat); Antipsychotic; Cognition; Exposure; Serum level

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HISTAMINE H1 RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; SERTINDOLE;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; EXPERIMENTAL DESIGN; HYPOTHESIS; IMMERSION; IN VIVO STUDY; LATENT PERIOD; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RODENT; TASK PERFORMANCE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; INDOLES; MALE; MAZE LEARNING; PSYCHOMOTOR PERFORMANCE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 33745979179     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.05.021     Document Type: Article

References (52)

1. Addington J., and Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr. Bull. 25 (1999) 173-182
2. Aravagiri M., Teper Y., and Marder S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm. Drug Dispos. 20 (1999) 369-377
3. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur. J. Pharmacol. 283 (1995) 55-62
4. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
5. Beuzen J.N., Taylor N., Wesnes K., and Wood A. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. J. Psychopharmacol. 13 (1999) 152-158
6. Bymaster F.P., Nelson D.L., DeLapp N.W., Falcone J.F., Eckols K., Truex L.L., Foreman M.M., Lucaites V.L., and Calligaro D.O. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr. Res. 37 (1999) 107-122
7. Chesler E.J., and Salamone J.D. Effects of acute and repeated clozapine injections on cholinomimetic-induced vacuous jaw movements. Pharmacol. Biochem. Behav. 54 (1996) 619-624
8. Cleghorn J.M., Kaplan R.D., Szechtman B., Szechtman H., and Brown G.M. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr. Res. 3 (1990) 211-219
9. Cutmore T.R.H., and Beninger R.J. Do neuroleptics impair learning in schizophrenic patients. Schizophr. Res. 3 (1990) 173-186
10. D'Hooge R., and De-Deyn P.P. Applications of the Morris water maze in the study of learning and memory. Brain Res. Rev. 36 (2001) 60-90
11. Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. Eur. J. Pharmacol. 281 (1995) 241-250
12. Didriksen M., and Sams-Dodd F. Effects of haloperidol, clozapine, and sertindole on cognitive function in rats after chronic treatment. Soc. Neurosci. Abstr. 23 (1997) 1932
13. Fabrazzo M., La Pia S., Monteleone P., Esposito G., Pinto A., De Simone L., Bencivenga R., and Maj M. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology 27 (2002) 1050-1055
14. Fitton A., and Heel R.C. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40 (1990) 722-747
15. Fulton B., and Goa K.L. Olanzapine, a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53 (1997) 281-298
16. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Pickar D., Schulz S.C., and Weinberger D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry 162 (1993) 43-48
17. Goldberg T.E., Ragland D., Torrey E.F., Gold J.M., Bigelow L.B., and Weinberger D.R. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch. Gen. Psychiatry 47 (1990) 1066-1072
18. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J. Psychiatry 153 (1996) 321-330
19. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 26 (2000) 119-136
20. Harvey P.D., Parrella M., White L., Mohs R.C., Davidson M., and Davis K.L. Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr. Res. 35 (1999) 77-84
21. Hoff A.L., Faustman W.O., Wieneke M., Espinoza S., Costa M., Wilkowitz O., and Csernansky J.G. The effect of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 15 (1996) 361-369
22. Kane J.M., and Tamminga C.A. Sertindole (serdolect): preclinical and clinical findings of a new atypical antipsychotic. Exp. Opin. Invest. Drugs 6 (1997) 1729-1741
23. Kapur S., Zipursky R.B., and Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156 2 (1999) 286-293
24. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol. Exp. Ther. 305 (2003) 625-631
25. Lavalaye J., Booij J., Linszen D.H., Reneman L., and van Royen E.A. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia, A[123I]-IDEX SPECT study. Psychopharmacology (Berl.) 156 (2001) 53-57
26. Lis S., Krieger S., Gallhofer B., Torre P., Mittoux A., and Menard F. Sertindole is superior to haloperidol in cognitive performance in patients with schizophrenia: a comparative study. Eur. Neuropsychopharmacol. 13 (2003) S323-S324
27. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25 (1999) 233-255
28. Morris R.G.M. Developments of a water maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11 (1984) 47-60
29. Mortimer A.M. Cognitive function in schizophrenia-do neuroleptics make a difference?. Pharmacol. Biochem. Behav. 56 (1997) 789-795
30. Nyberg S., Olsson H., Nilsson U., Maehlum E., Halldin C., and Farde L. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl.) 162 (2002) 37-41
31. Okamura N., Yanai K., Higuchi M., Sakai J., Iwata R., Ido T., Sasaki H., Watanabe T., and Itoh M. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br. J. Pharmacol. 129 (2000) 115-123
32. Peretti C.S., Danion J.M., Kauffmann-Muller F., Grange D., Patat A., and Rosenzweig P. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers. Psychopharmacology (Berl.) 131 (1997) 329-338
33. Perry P.J., Sanger T., and Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J. Clin. Psychopharmacol. 17 (1997) 472-477
34. Riekkinen P.J., Sirvio J., Aaltonen M., and Riekkinen P. Effects of concurrent manipulations of nicotinic and muscarinic receptors on spatial and passive avoidance learning. Pharmacol. Biochem. Behav. 37 (1990) 405-410
35. Sanchez C., and Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol. Biochem. Behav. 77 (2004) 391-398
36. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van G.P., Lesage A.S., De L.K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.) 124 (1996) 57-73
37. Sevy S., and Davidson M. The costs of cognitive impairment in schizophrenia. Schizophr. Res. 17 (1995) 1-3
38. Siegel S. Nonparametric Statistics for the Behavioral Sciences (1956), McGraw-Hill, New York
39. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. Psychopharmacology (Berl.) 124 (1996) 126-133
40. Tamminga C.A., Mack R.J., Granneman G.R., Silber C.J., and Kashkin K.B. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int. Clin. Psychopharmacol. 12 (1997) S29-S35
41. Tashiro M., Mochizuki H., Iwabuchi K., Sakurada Y., Itoh M., Watanabe T., and Yanai K. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci. 72 (2002) 409-414
42. Terry Jr. A.V., Hill W.D., Parikh V., Evans D.R., Waller J.L., and Mahadik S.P. Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology (Berl.) 164 (2002) 360-368
43. Tollefson G.D. Cognitive function in schizophrenic patients. J. Clin. Psychiatry 57 (1996) 31-39
44. Varvel S.A., Vann R.E., Wise L.E., Philibin S.D., and Porter J.H. Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology (Berl.) 160 (2002) 182-191
45. Velling D.I., Mahurin R.K., Diamond P.L., Hazleton B.C., Eckert S.L., and Miller A.L. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 25 (1997) 21-31
46. Vitiello B., Martin A., Hill J., Mack C., Molchan S., Martinez R., Murphy D.L., and Sunderland T. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology 16 (1997) 15-24
47. Weinberger D.R., and Gallhofer B. Cognitive function in schizophrenia. Int. Clin. Psychophrarmacol. 12 (1997) S29-S36
48. Weiner D.M., Meltzer H.Y., Veinbergs I., Donohue E.M., Spalding T.A., Smith T.T., Mohell N., Harvey S.C., Lameh J., Nash N., Vanover K.E., Olsson R., Jayathilake K., Lee M., Levey A.I., Hacksell U., Burstein E.S., Davis R.E., and Brann M.R. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl.) 177 (2004) 207-216
49. Wolff M.C., and Leander J.D. Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. Psychopharmacology (Berl.) 168 (2003) 410-416
50. Zeng X.P., Le F., and Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol. 321 (1997) 349-354
51. Zhang W., and Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl.) 141 (1999) 267-278
52. Zorn S.H., Jones S.B., Ward K.M., and Liston D.R. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur. J. Pharmacol. 269 (1994) R1-R2